Common TitleAPV109141
Official Title Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.
Phase Phase III
ClinicalTrials.gov NCT00450580
Treatments
Fosamprenavir
Fosamprenavir
Tradename:LexivaOther Names:FPVClass:Protease Inhibitors (PI)Categories Treatment-Naive
Funding
IndustryViiV Healthcare
References
- Carosi G, Lazzarin , Stellbrink H, et al. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects. HIV Clin Trials. 2009;10:356-67.